These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 24525661

  • 1. The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial.
    Schoemaker JH, Jansen WT, Schipper J, Szegedi A.
    J Clin Psychopharmacol; 2014 Apr; 34(2):190-8. PubMed ID: 24525661
    [Abstract] [Full Text] [Related]

  • 2. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
    Umbricht D, Alberati D, Martin-Facklam M, Borroni E, Youssef EA, Ostland M, Wallace TL, Knoflach F, Dorflinger E, Wettstein JG, Bausch A, Garibaldi G, Santarelli L.
    JAMA Psychiatry; 2014 Jun; 71(6):637-46. PubMed ID: 24696094
    [Abstract] [Full Text] [Related]

  • 3. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
    Lerner V, Miodownik C, Gibel A, Sirota P, Bush I, Elliot H, Benatov R, Ritsner MS.
    J Clin Psychiatry; 2013 Dec; 74(12):1224-32. PubMed ID: 24434091
    [Abstract] [Full Text] [Related]

  • 4. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
    Weiser M, Heresco-Levy U, Davidson M, Javitt DC, Werbeloff N, Gershon AA, Abramovich Y, Amital D, Doron A, Konas S, Levkovitz Y, Liba D, Teitelbaum A, Mashiach M, Zimmerman Y.
    J Clin Psychiatry; 2012 Jun; 73(6):e728-34. PubMed ID: 22795211
    [Abstract] [Full Text] [Related]

  • 5. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study.
    Kane JM, Yang R, Youakim JM.
    Schizophr Res; 2012 Mar; 135(1-3):116-22. PubMed ID: 22178084
    [Abstract] [Full Text] [Related]

  • 6. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
    Khodaie-Ardakani MR, Seddighi S, Modabbernia A, Rezaei F, Salehi B, Ashrafi M, Shams-Alizadeh N, Mohammad-Karimi M, Esfandiari GR, Hajiaghaee R, Akhondzadeh S.
    J Psychiatr Res; 2013 Apr; 47(4):472-8. PubMed ID: 23375406
    [Abstract] [Full Text] [Related]

  • 7. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study.
    Rezaei F, Mohammad-Karimi M, Seddighi S, Modabbernia A, Ashrafi M, Salehi B, Hammidi S, Motasami H, Hajiaghaee R, Tabrizi M, Akhondzadeh S.
    J Clin Psychopharmacol; 2013 Jun; 33(3):336-42. PubMed ID: 23609382
    [Abstract] [Full Text] [Related]

  • 8. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
    Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, Tun R, Chang YC, Tsai GE.
    JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
    [Abstract] [Full Text] [Related]

  • 9. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia.
    Lieberman JA, Papadakis K, Csernansky J, Litman R, Volavka J, Jia XD, Gage A, MEM-MD-29 Study Group.
    Neuropsychopharmacology; 2009 Apr; 34(5):1322-9. PubMed ID: 19005465
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia.
    Dunayevich E, Buchanan RW, Chen CY, Yang J, Nilsen J, Dietrich JM, Sun H, Marder S.
    Schizophr Res; 2017 Apr; 182():90-97. PubMed ID: 27789188
    [Abstract] [Full Text] [Related]

  • 11. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
    Möller HJ, Riedel M, Müller N, Fischer W, Kohnen R.
    Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
    [Abstract] [Full Text] [Related]

  • 12. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
    Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT.
    Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
    [Abstract] [Full Text] [Related]

  • 13. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL, Burns T, Morosini P, Gagnon DD, Rothman M, Adriaenssen I.
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [Abstract] [Full Text] [Related]

  • 14. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
    Olié JP, Spina E, Murray S, Yang R.
    Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L, Meng X, Hochfeld M, Stahl SM.
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [Abstract] [Full Text] [Related]

  • 16. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D, Fernandes BS, Berk M, Dodd S, Medeiros DW, Pedrini M, Kunz M, Gomes FA, Giglio LF, Lobato MI, Belmonte-de-Abreu PS, Gama CS.
    J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
    [Abstract] [Full Text] [Related]

  • 17. Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo.
    Stauffer VL, Millen BA, Andersen S, Kinon BJ, Lagrandeur L, Lindenmayer JP, Gomez JC.
    Schizophr Res; 2013 Nov; 150(2-3):434-41. PubMed ID: 24035403
    [Abstract] [Full Text] [Related]

  • 18. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G, Trixler M, Bitter I, Degrell I, Füredi J, Faludi G, Ziprasidonra Váltást Vizsgáló Munkacsoport.
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
    [Abstract] [Full Text] [Related]

  • 19. Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia.
    Grant PM, Huh GA, Perivoliotis D, Stolar NM, Beck AT.
    Arch Gen Psychiatry; 2012 Feb; 69(2):121-7. PubMed ID: 21969420
    [Abstract] [Full Text] [Related]

  • 20. Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial.
    Ritsner MS, Bawakny H, Kreinin A.
    Psychiatry Clin Neurosci; 2014 Jun; 68(6):432-40. PubMed ID: 24548129
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.